A UK consensus on the administration of aripiprazole for the treatment of mania

Journal of Psychopharmacology

Volumn 23, Issue 3, 2009, Pages 231-240

  Aitchison, K J ^a   Bienroth, M ^b   Cookson, J ^c   Gray, R ^d   Haddad, P M ^e   Moore, B ^f   Ratna, L ^g   Sullivan, G ^h   Taylor, D ⁱ   Taylor, M ^j   Goodwin, G M ^k  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^e GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^f 5 Boroughs Partnership NHS Trust   (United Kingdom)

^g Barnet Enfield Haringey Mental H   (United Kingdom)

^h UNIVERSITY OF GLAMORGAN   (United Kingdom)

ⁱ SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^j NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^k UNIVERSITY OF OXFORD   (United Kingdom)

more..

Author keywords

Algorithms; Antipsychotic agents administration and dosage; Antipsychotic agents therapeutic use; Bipolar disorder drug therapy; Guideline; Mania

Indexed keywords

ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CARBAMAZEPINE; DOMPERIDONE; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; LORAZEPAM; OLANZAPINE; PAROXETINE; PLACEBO; PROPRANOLOL; VALPROIC ACID;

ADVERSE OUTCOME; AGITATION; AKATHISIA; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FRACTURE; HUMAN; INSOMNIA; LEG PAIN; LITERATURE; MUSCULOSKELETAL STIFFNESS; NAUSEA; OSTEOPENIA; PRESCRIPTION; PRIORITY JOURNAL; RESTLESSNESS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED KINGDOM; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; GREAT BRITAIN; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; QUINOLONES;

EID: 65349101102     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108098820     Document Type: Article

References (48)

1. Aitchison KJ, Gonzalez FJ, Quattrochi LC, Sapone A, Zhao JH, Zaher H, (2000) Identification of novel polymorphisms in the 5' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance. Pharmacogenetics 10: 695 - 704.
2. Allen MH, Currier GW, Carpenter D, Ross RW, Docherty JP, Expert Consensus Panel for Behavioral Emergencies 2005. (2005) The expert consensus guideline series. Treatment of behavioral emergencies 2005. J Psychiatr Pract 11 (Suppl. 1). 5 - 108.
3. APA (2004) Practice Guidelines for the Treatment of Patients with Schizophrenia, Second Edition. Am J Psychiatry 161: 1 - 56.
4. Boulton D, Vanderslice T, Kornhauser D, Geraldes M, Kollia G, Vaccharajani N, (2004) Effects of aripiprazole on the steady-state pharmacokinetics of valproic acid. Eur Neuropsychopharmacol 14: 291.
5. Boulton DW, Balch AH, Royzman K, Patel CG, Berman RM, Mallikaarjun S, (2008) The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. Psychopharmacol. Online First: 0269881108096522.
6. Bowden CL, Grunze H, Mullen J, Brecher M, Paulsson B, Jones M, (2005) A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 66: 111 - 121.
7. Brown ES, Jeffress J, Liggin JDM, Garza M, Beard L, (2005) Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry 66: 756 - 760. (Pubitemid 40942423)
8. Buckley PF, (2007) Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 68 (Suppl. 6). 5 - 9.
9. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S, (2005) Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 45: 89 - 93.
10. DeLeon A, Patel NC, Crismon ML, (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26: 649 - 666.
11. Goodwin FK, Jamison KR, (2007) Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. New York: Oxford University Press.
12. Goodwin GM, (2003) Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 17: 149 - 173 (discussion 147).
13. Haddad PM, Sharma SG, (2007) Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 21: 911 - 936.
14. Heinrichs DW, Hanlon TE, Carpenter WT, (1984) The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 10: 388 - 398.
15. Hirschfeld RM, Keck PE, Kramer M, Karcher K, Canuso C, Eerdekens M, (2004) Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 161: 1057 - 1065.
16. Keck PE, Ronald M, Stavros T, Mirza A, Amy L, Anutosh S, (2003a) A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 160: 1651 - 1658.
17. Keck PE, Versiani M, Potkin S, West SA, Giller E, Ice K, (2003b) Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 160: 741 - 748.
18. Keck PE, Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, (2006) A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 67: 626 - 637.
19. Keck PE, Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, (2007) Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 68: 1480 - 1491.
20. Keck PE, Orsulak PJ, Cutler AJ, Sanchez R, Torbeyns A, Marcus RN, (2008) Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. Journal of Affective Disorders: In press.
21. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M, (2005) Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 187: 229 - 234.
22. Kornhauser D, Boulton D, Mallikaarjun S, Geraldes M, Dressler D, Carson W, (2005) Effects of aripiprazole on pharmacokinetics of lithium in healthy subjects. Presented at the American Psychiatric Association 158th Annual Meeting, Atlanta, GA, USA, May 21-26.
23. Maguire G, (2002) Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 63: 56 - 62.
24. McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J, (2005a) Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 15: 573 - 585.
25. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH, (2005b) Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 17: 83 - 93.
26. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CW, Miranda A, (2007) Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry 20: 406 - 416.
27. Mir A; ,Shivakumar K; ,Williamson RJ; ,McAllister V; ,O'Keane V; ,Aitchison KJ; , (2008) Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 22: 323-329.
28. Moore BJ; , (2004) Atypicals versus conventional treatment for bipolar disorder. Hospital Doctor, Psychiatry Supplement, December 2, 10-11.
29. National Collaborating Centre for Mental Health (2006) National Institute for Health and Clinical Excellence, London.
30. Newcomer JW, (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19: 1 - 93.
31. Ohlsen R, Williamson R, Yusufi B, Mullan J, Irving D, Mukherjee S, (2008) Interrater reliability of the antipsychotic non-neurological side-effects rating scale (ANNSERS). Journal of Psychopharmacology 22: 323 - 329.
32. Potkin SG, Keck PE, Segal S, Ice K, English P, (2005) Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 25: 301 - 310.
33. Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, (2006) Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 20: 536 - 546.
34. Scheen AJ, De Hert MA, (2007) Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 33: 169 - 175.
35. Schieber F, Boulton D, Balch A, Croop R, Mallikaarjun S, Benson J, (2007) A non-randomized study to investigate the effects of aripiprazole on the steady-state pharmacokinetics of lamotrigine in subjects with bipolar I disorder. Poster presented at ASHP 2007.
36. Seeman MV, (2001) Clinical trials in psychiatry: do results apply to practice. Can J Psychiatry 46: 352 - 355.
37. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F, (2005) Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 15: 75 - 84.
38. http://www.emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp? documentid=18494
39. Sullivan G, Bienroth M, Jones M, Millar H, Ratna L, Taylor D, (2007) Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel. Curr Med Res Opin 23: 1733 - 1744. (Pubitemid 47122182)
40. Suppes T, Eudicone J, McQuade R, Pikalov A, 3rd and Carlson B, (2008) Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord 107: 145 - 154.
41. Taylor V, MacQueen G, (2006) Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 67: 1034 - 1041.
42. Tohen M, Jacobs TG, Grundy SL, McElroy SL, Banov MC, Janicak PG, (2000) Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 57: 841 - 849.
43. Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, (1999) Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 156: 702 - 709.
44. Vestergaard P, (2004) Guidelines for maintenance treatment of bipolar disorder: are there discrepancies between European and North American recommendations. Bipolar Disord 6: 519 - 522.
45. Vieta E, Bourin M, Sanchez R, Marcus R, Stock E, McQuade R, (2005) Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 187: 235 - 242.
46. Vieta E, T?joen C, McQuade RD, Carson WH, Marcus RN, Sanchez R, (2008) Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). American Journal of Psychiatry: Published online April 1; doi:10.1176/appi.ajp.2008.07101560
47. Young A, Lowy F, McQuade R, Sanchez R, Torbeyns A, (2008) Aripiprazole monotherapy in acute bipolar I mania: a 12-week, randomized, placebo- and haloperidol- controlled study (CN138-162). British Journal of Psychiatry: In press.
48. Zimbroff DL, Marcus RN, Manos G, Stock E, McQuade RD, Auby P, (2007) Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 27: 171 - 176.